This comprehensive safety meta-analysis confirms the safety profile for patients treated with Cerebrolysin after acute ischemic stroke, as compared to placebo. We observed a tendency of superiority of Cerebrolysin regarding SAE in high dose treatment courses for moderate-severe ischemic stroke, suggesting some effect of the agent against adverse events. The lowest rate of Serious Adverse Events (SAE), as compared to placebo, was observed for the highest dose of Cerebrolysin (50 mL), highlighting a moderate reduction (RR = 0.6). The meta-analysis pooled 2202 patients from twelve randomized clinical trials, registering non-statistically significant (p>0.05) differences between Cerebrolysin and placebo throughout main and subgroup analyses. All safety outcomes were analyzed based on risk ratios (RR) and their 95% confidence intervals. Data collection and analysis was conducted using methods described in the Cochrane Handbook for Systematic Reviews of Interventions. We searched EMBASE, PubMed and Cochrane Databases of Systematic Reviews and Clinical Trials up to the end of February 2021. Benefits are greater with better compliance to the diet.We performed a systematic search and meta-analysis of available literature to determine the safety profile of Cerebrolysin in acute ischemic stroke, filling existing safety information gaps and inconsistent results. Other lipids and glucose were not different.Ībstract: Conclusion: The short term benefit of higher protein diets appears to persist to a small degree long term. Fasting triglyceride and insulin were also lower with high protein diets with effect sizes of 0.17 and 0.22, p = 0.003 and p = 0.042 respectively.
A difference of 5% or greater in percentage protein between diets at 12mo was associated with a 3 fold greater effect size compared with <5% (p = 0.038) in fat mass (0.9 vs. A recommendation to consume a lower carbohydrate, higher protein diet in mostly short term intensive interventions with long term follow up was associated with better weight and fat loss but the effect size was small-standardised means of 0.14 and 0.22, p = 0.008 and p < 0.001 respectively (equivalent to 0.4 kg for both). As many as 32 studies with 3492 individuals were analysed with data on fat and lean mass, glucose and insulin from 18 to 22 studies and lipids from 28 studies. Data was analysed using Comprehensive Meta analysis V2 using a random effects analysis. Studies were selected regardless of the success of the advice but difference in absolute and percentage protein intake at 12 months was used as a moderator in the analysis. Whether this benefit persists long term is not clear.Ībstract: Methods and results: We selected weight loss studies in adults with at least a 12 month follow up in which a higher percentage protein/lower carbohydrate diet was either planned or would be expected for either weight loss or weight maintenance. 224-235 24 3 224 235Ībstract: Background: Meta analysis of short term trials indicates that a higher protein, lower carbohydrate weight loss diet enhances fat mass loss and limits lean mass loss compared with a normal protein weight loss diet. Published In: Nutrition, metabolism and cardiovascular diseases vol.
Title: Long term weight maintenance after advice to consume low carbohydrate, higher protein diets: a systematic review and meta analysisĪuthor: Clifton, PM author School of Pharmacy and Medical Sciences, University of South AustraliaĪuthor: Condo, D author Flinders UniversityĪuthor: Keogh, Jennifer Beatrice author School of Pharmacy and Medical Sciences, University of South Australia